Quarterly report Q2 2026

The information was provided for publication on August 27, 2026.

PROLIGHT
Diagnostics you can count on

TABLE OF CONTENTS

Second quarter, April 1 – June 30, 2026

(Figures in parentheses refer to the corresponding period in the previous year.)

- Net sales amounted to 0 (0).
- Other operating income amounted to 2,840 (13,945) thousand SEK.
- Operating profit (EBIT) amounted to -8,304 (-15,346) thousand SEK.
- Profit after tax amounted to -8,304 (-12,740) thousand SEK.
- Earnings per share before and after dilution: -0.69 (-1.81) SEK.
- Cash flow from operating activities was 7,766 (-4,699) thousand SEK.

First half of the year, January 1 – June 30, 2026

(Figures in parentheses refer to the corresponding period in the previous year.)

- Net sales amounted to 0 (0).
- Other operating income amounted to 4,042 (15,607) thousand SEK.
- Operating profit (EBIT) amounted to -18,694 (-26,281) thousand SEK.
- Profit after tax amounted to -18,694 (-26,281) thousand SEK.
- Earnings per share before and after dilution: -1.55 (-3.38) SEK.
- Cash flow from operating activities was -4,874 (-13,875) thousand SEK.

Significant events during the quarter

- Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.
- Positive patent decision in Japan.
- Design freeze achieved for the Psyros instrument.
- Positive patent decision in the United States.

Significant events after the end of the period

- A feasibility study, on traumatic brain injury (TBI), involving 260 patient samples demonstrated excellent results and formed the basis for the signing of a SEK 29 million development agreement with BRAINBox Solutions.

Financial calendar

November 26, 2026
Interim Report Q3

February 25, 2027
Year End Report

May 26, 2027
Interim report Q1

May 26, 2027
Annual General Meeting

CEO statement

Strong momentum following successful BRAINBox results

The second quarter of 2026 has been one of the most significant quarters in Prolight's history. After several years of intensive product development, we have now taken a decisive step from technology verification to commercial validation. Most notably, the strong results from our study with BRAINBox Solutions have again confirmed the Psyros platform's ability to deliver laboratory-quality performance at the point of care, generating substantially increased interest from the diagnostics industry.

During the quarter, we continued our efforts to finalize and industrialize the Psyros system while also achieving important advances in both product development and intellectual property. We received positive patent notifications in two of the world's most important markets, Japan and the United States, further strengthening the protection of our unique technology and our long-term commercial opportunities.

The most important event of the quarter occurred after the reporting period when results from the traumatic brain injury (TBI) study involving 260 patient samples demonstrated excellent performance. The study showed the Psyros platform's ability to measure TBI biomarkers with high sensitivity at the point of care while delivering performance comparable to central laboratory testing. The results were sufficiently compelling to form the basis of a development agreement with BRAINBox Solutions valued at approximately SEK 29 million.

The agreement is significant for several reasons. In addition to the direct funding, it represents clear external validation of he Psyros technology by a leading company in traumatic brain injury diagnostics. The collaboration also demonstrates how rapidly new biomarkers can be implemented on our platform and highlights Psyros' potential across multiple clinical applications beyond cardiac biomarkers.

The positive study data generated using both high-sensitivity troponin assays and TBI biomarkers has contributed to a clear shift in how the market views Psyros. Discussions with potential partners are increasingly focused on commercial implementation rather than on proving the technology itself. We are seeing growing interest from diagnostic companies, industry partners and distributors who recognise the need for cost-effective point-of-care testing that delivers laboratory-quality results.

This was particularly evident at ADLM 2026, one of the world's leading congresses for laboratory medicine and diagnostics. Many meetings were conducted with potential commercial partners interested in discussing strategic collaborations and future market opportunities for the Psyros platform. This increased interest reinforces our belief that the market is seeking next-generation point-of-care capable of combining laboratory-quality performance with speed, ease of use and cost efficiency.

We enter the autumn with stronger commercial momentum than ever before. Our focus going forward will be on validating manufacturing processes and initiating pilot production of the first commercial products. At the same time, discussions with potential strategic partners continue and have intensified following the positive outcomes from the BRAINBox collaboration and our presence at ADLM.

Finally, I would like to thank our employees, partners and shareholders for your continued support.

Lund, August 2026

Ulf Bladin
CEO, Prolight Diagnostics (publ)

Safe point-of-care test enable faster diagnostics

Prolight Diagnostics has, over a long period, observed a sharply increasing demand for user-friendly and near-patient analysis systems, so-called Point-of-Care ("POC") systems. A couple of examples are the mergers and acquisitions that have taken place. For example, Roche's acquisition of LumiraDx for 295 MUSD in 2023 and bioMerieux's purchase of Spinchip in 2025 for 138 MEUR and the purchase of Specific Diagnostics for 417 MUSD in 2022. Additionally, Thermo Fisher Scientific's acquisition of Mesa BioTech in 2021 for USD 450 million and Abbott's acquisition of Alere for USD 5.8 billion already in 2016 show the strong interest.

Primary and elderly care, emergency departments and ambulances demand fast, reliable blood test results when the patient is first examined instead of being forced to submit blood samples to hospital laboratories and wait hours or days for results, which is currently the case. Access to point-of-care analyses is especially important in acute conditions, such as for patients exhibiting acute chest pain and suspected myocardial infarction. In these situations, it is critical to make an early and correct diagnosis and initiate adequate treatment to save lives.

To meet this demand, Prolight has developed a new and flexible POC system, Psyros®, which can perform In-Vitro Diagnostic (IVD) tests with the same sensitivity and precision as hospital laboratories but with the difference that test results can be given already within ten minutes or less. By obtaining these test results early in the patient care continuum, doctors and healthcare professionals can make the correct diagnosis and prioritise adequate resources for the right patient. As a result, substantial cost savings can also be realized in the heavily burdened healthcare system.

The new digital immunoassay technology, Psyros, was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics Ltd, which has developed a new, cutting-edge POC technology for digital immunoassay. The wholly owned subsidiary Psyros Diagnostics currently has a highly competent team with long and broad experience in IVD development, especially in POC tests and POC systems.

The team has unique competencies and experiences vital to the company's continued development. Prolight's pioneering IP-protected POC technology counts individual molecules digitally from a drop of blood. This proprietary technology, which also has the possibility of multiplexing (testing several biomarkers at the same time), enables the measurement of biomarkers with extremely low detection levels (femtomolar 10-15) within approximately 10 minutes or less. To Prolight's knowledge, there is no other existing digital POC system deemed capable of performing these analyses at extremely low concentrations with such simplicity, precision, and low production costs. The system consists of an easy-to-use disposable cartridge and a portable analysis unit. Only a drop of blood is required to perform the test.

The cutting-edge technology is being used, among other applications, to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy to aid in the rule-in and rule-out of myocardial infarction. By measuring the biomarker troponin, which is released from the heart into the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The test places great demands on sensitivity and precision and has a substantial global sales potential.

The technology also opens up the possibilities of being able to develop and analyze new POC tests in a number of different clinical areas that were previously only possible to carry out in specialized laboratories. Prolight has been able to demonstrate that its digital ultra-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per liter (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of what is required to rule out myocardial infarction with high-sensitivity troponin assays[1].

Proof-of-performance results were obtained partly in November 2022 by measuring the levels of thyroid-stimulating hormone (TSH) in human plasma samples, partly in June 2023 by measuring high-sensitivity troponin in serum samples, and also

1 European Cardiology Society´s Guidelines on Fourth Universal Definition of Myocardial infarction.

in November 2023 when the company was able to show that the system for detecting single molecules provides equivalent performance in whole blood compared to plasma, without the need to separate the cells from the sample. This reduces complexity and paves the way for an extremely competitive price level.

The final development work focuses on optimizing the IP-protected POC technology for digital immunoanalysis. An extensive preclinical evaluation of approximately 30 instrument prototypes confirmed the system's technical performance and provided a strong basis for implementing a limited number of targeted improvements focused on long-term robustness and scalability. In April 2026, the Company formally achieved design freeze for the instrument, marking a major and decisive step towards scalable manufacturing and clinical use. The completed design enables pilot production of instruments to be used for verification and validation, followed by the regulatory clinical performance study in Europe and the UK, and subsequently in the United States.

In March and July 2026, positive results were announced from a collaboration with BRAINBox Solutions, a leading developer of multimodal diagnostic and prognostic tests for traumatic brain injury (TBI).

The analytical evaluation in March 2026 demonstrated excellent performance for a unique combination of three TBI biomarkers, highlighting how readily new markers can be transferred onto the Psyros platform, which is based on single-molecule counting. This further strengthens the platform's potential to improve patient care across a broad range of clinical applications.

The results are consistent with previously reported preclinical data demonstrating the ability of Psyros to deliver laboratory-quality results, detecting biomarkers at extremely low concentrations within minutes using only a small sample volume. The study was fully funded by BRAINBox, headquartered in Richmond, Virginia.

Based on these results, Prolight and BRAINBox advanced to the next phase of the BRAINBox funded programme, in which all three assays were evaluated using a biobank comprising 260 patient samples. The results were excellent and provided the foundation for the signing of a SEK 29 million development agreement with BRAINBox. The development agreement covers the development of advanced multiplex cartridges, software and the initial purchase of pilot instruments.

The samples represent a subset of more than 2,000 samples available from BRAINBox's ongoing pivotal registration study, HeadSMART II, which is evaluating the company's diagnostic and prognostic test for mild traumatic brain injury, BRAINBox TBI, in preparation for regulatory submission to the U.S. Food and Drug Administration (FDA). The assay format utilizes Psyros multiplex-capable test cartridges with dry reagents, enabling scalable and cost-efficient manufacturing—an important advantage in TBI and other conditions requiring high-precision measurement of multiple analytes. Regulatory approval of the BRAINBox system would also mark the U.S. market approval of the Psyros platform, representing a key milestone for Prolight.

Vision, mission & Strategy

Vision
Pioneering the next frontier in lifesaving diagnostic insights.

Mission
To make high-sensitivity biomarker testing available wherever care happens — delivering trusted results in minutes, so clinicians can act faster, health systems can operate more efficiently, and patients everywhere can achieve better outcomes.

Strategy
Prolight's strategy is to establish Psyros® as a leading and cost-effective point-of-care platform for high-sensitivity biomarker testing. The platform is initially being developed for areas with significant unmet medical needs, such as cardiovascular and neurological conditions, but has the potential to be used across a broad range of clinical applications.

By enabling rapid and reliable test results close to the patient within 10 minutes, Psyros has the potential to support more efficient clinical workflows, reduce healthcare costs and improve patient outcomes.

Point-of-Care

Point-of-Care – a rapidly growing global market

There is an acute awareness of the value of rapid, accurate, and efficient testing near the patient. The market demands that more tests are moved out from large hospital laboratories and closer to the patient and care giver. POC tests can also help reduce healthcare costs by giving faster results and more rapid treatment. Throughout the Covid pandemic, the use of POC testing increased substantially. This led to an acute awareness of the value of rapid, simple, and efficient testing and analysis near the patient. Most companies, healthcare providers, politicians and the general public realize the value of these tests, benefitting patients, clinicians, and healthcare in general. This interest has, in turn, created a need for new technologies that can meet the challenges of more demanding tests, whilst still being competitively priced.

According to Precedence research, the POC market is expected to grow from approximately USD 44,5 billion in 2025 to approximately USD 125.3 billion in 2034[2].

The global market for cardiac biomarkers
The global market for cardiac biomarkers was approximately USD 12,3 billion in 2025 and is expected to grow by approximately 7.2 percent per year until 2034, reaching an estimated USD 23.3 billion by 2034[3].

When it comes to point-of-care (POC) testing for cardiac biomarkers, market growth is being driven by the increasing number of patients with cardiovascular diseases and growing awareness of the importance of early diagnosis. Early diagnosis enables faster and more appropriate medical interventions for the right patients.

The global market for troponin
The global market for troponin was approximately USD 1.6 billion in 2024 and is expected to grow by approximately 12.6 percent per year until 2033, reaching an estimated USD 4.1 billion by 2034[4].

Trends favoring the market development of POC tests
The main driving forces behind the general growth of POC tests are considered to be increased demand for central laboratory tests that are moved closer to the patient, e.g. to emergency departments, primary care, ambulances and nursing homes, rapid technical development, digitization within healthcare, increasing investments in research and development as well as an ageing population in the West.

Global market and Compound Annual Growth Rate (CAGR)



2 https://www.precedenceresearch.com/point-of-care-testing-market
3 https://www.imarcgroup.com/cardiac-biomarkers-market
4 https://www.insightaceanalytic.com/report/troponin-diagnostic-tests-market/3314

Groundbreaking ultra-sensitive POC technology

Prolight is poised to deliver the most innovative and best-inclass POC systems on the market

Prolight is well-positioned to deliver POC systems to satisfy several clinical unmet needs. These include high sensitive troponin, other biomarkers in many diverse clinical areas as well as assays currently not available at POC and multiplex assays for measuring several analytes simultaneously.

A new ground-breaking POC technology for digital immunoassay
Prolight has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique IP-protected technology opens the possibility of developing several new POC tests and analysis in a wide range of clinical areas where many of them previously have only been possible to analyse in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.

Detection limit at the level of PCR tests, but with significantly faster response time
Today, PCR tests are recommended to confirm respiratory infections, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today's PCR tests and Prolight's innovative digital POC platform is that the response time can be reduced to just ten minutes or less.

A start of a paradigm shift in POC testing
This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. Examples of possible future clinical areas are: Traumatic Brain Injury (as our cooperation with Brainbox illustrates), other Neurological pathologies, Immune system dysfunction (sepsis, autoimmune diseases), Sexually Transmitted Infections, Rapid virus detection such as in respiratory or urinary infections.. The unique and IP-proteced technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument.

Future applications across many diverse clinical areas

The patent portfolio for the Psyros single molecule counting technology

Prolight have six families of patent applications relating to the Psyros single-molecule-counting technology. The first five families are currently in the national / regional phases in a range of territories worldwide. The sixth patent application entered the PCT (patent cooperation treaty) international phase in November 2025.

The first 2 patents were granted in Europe in Q2 2025 by the European Patent Office (EPO) and have now been validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of approximately 540 million people. A third patent was granted in Europe in December 2025 and has been validated in 11 European jurisdictions.

The first 2 patents were granted by the Japan Patent Office (JPO) in July 2025 and April 2026 respectively.

Notices of Allowance were received in July 2026 for the first patent in Korea (MOIP) and the second patent in the United States (USPTO) and these patents are expected to be granted shortly.

Family 1 patent (EP3987287 and JP7700055) protects the core technology and will remain in force until 2040.

Family 2 patent (EP4264266 and JP7867712) is an enhancement to the core technology and will remain in force until 2041.

Family 3 patent (EP4496995) uses 2 wavelengths to enhance signal generation and will remain in force until 2042.

A divisional application of family 1 patent (EP3987287) has also been filed (published as EP4549943) to seek greater scope for the core technology.

Owners

Owners list as of 2026-06-30

	Holdings 2026-06-30	Votes in %
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	667,841	5.54
NORDNET PENSIONSFÖRSÄKRING AB	537,343	4.46
INTEGRATED TECHNOLOGIES LTD	493,720	4.10
STEVEN ANDREW ROSS	324,782	2.70
AILEEN JANE MCGETTRICK	318,295	2.64
PAUL BRENDAN MONAGHAN	318,295	2.64
JULIE RICHARDS	318,295	2.64
SWEDBANK FÖRSÄKRING AB	226,178	1.88
SEB LIFE INTERNATIONAL ASSURANCE	225,380	1.87
FREDRIK ALPSTEN	205,766	1.71
ULF BLADIN	191,428	1.59
KIARASH FARR	126,667	1.00
Total, 12 largest owners	**3,953,990**	**32,83**
Other	8,090,792	67,17
Total	**12,044,782**	**100.00**

Source: Euroclear

The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (corresponding to 83,045 shares) and 80,703 (corresponding to 80,703 shares) and can thus cause dilution.

Prolight Diagnostics' share is traded on the NGM Growth Market, under the name PRLD.

The Group's development during quarter 2, April 1 – June 30,2026

(figures in parentheses refer to the corresponding period in the previous year)

REVENUE

- During the product development period, the Group has no sales and net turnover.
- Other income for the quarter amounted to 2,840 (13,945) thousand SEK, consisting mainly of contributions and income received from the partner BRAINBox.

EXPENSES AND PROFITS

- The Group's total operating expenses during the quarter amounted to 18,104 (29,740) thousand SEK. The previous year's figures included an impairment loss relating to the adjustment of the additional purchase price.
- Other external expenses consist mainly of external expenses linked to the development of the Group's products.
- Capitalized work for own account amounted to 6,959 (449) thousand SEK and refers to costs for the Group's product development in the English subsidiary Psyros.

FINANCING AND CASH FLOW

- Cash flow from operating activities amounted to 7,766 (-4,699) thousand SEK.
- The Group's cash flow from investing activities amounted to -8,328 (-595) thousand SEK and in the quarter mainly consists of capitalized development costs of 6,959 (450) thousand SEK related to the Group's product development in the English subsidiary, Psyros.
- The total cash flow for the quarter was -561 (2,706) thousand SEK. The previous year's figures included a raised loan of 8,000 thousand SEK.
- During April 2026, the English subsidiary Psyros received 11 million SEK in "R&D tax credit", which improved liquidity by the same amount.

The Group's development during the first half of the year, January 1 to June 30 2026

(figures in parentheses refer to the corresponding period in the previous year)

REVENUE

- During the product development period, the Group has no sales and net turnover.
- Other income for the period amounted to 4,042 (15,607) thousand SEK, consisting mainly of contributions and income received from the partner BRAINBox.

EXPENSES AND PROFITS

- The Group's total operating expenses during the period amounted to 38,779 (45,110) thousand SEK. The previous year's figures included an impairment loss relating to the adjustment of the additional purchase price.
- Other external expenses consist mainly of external expenses linked to the development of the Group's products.
- Capitalized work for own account amounted to 16,043 (3,222) thousand SEK and refers to costs for the Group's product development in the English subsidiary Psyros.

FINANCING AND CASH FLOW

- Cash flow from operating activities amounted to –4,874 (-13,875) thousand SEK.
- The Group's cash flow from investing activities amounted to –19,133 (-3,506) thousand SEK and consists of mainly capitalized development costs of 16,043 (3,222) thousand SEK in the period linked to the Group's product development in the English subsidiary.
- The total cash flow for the period was -24,007 (-9,381). The previous year's figures included a loan of 8,000 thousand SEK.
- During April 2026, the English subsidiary Psyros received SEK 11 million in "R&D tax credit", which improved liquidity by the same amount.
- Liquid assets at the end of the period amounted to SEK 16,939 (5,652) thousand.

EQUITY, RECEIVABLES AND LIABILITIES
(figures in brackets refer to 2025-12-31)

- Equity in the Group amounted to SEK 151,162 (169,347) thousand as of June 30, 2026.
- Provisions amounted to SEK 14,419 (14,419) thousand and consist of a deferred tax liability relating to the acquired technology platform in the English subsidiary Psyros.
- Current receivables amounted to SEK 9,454 (17,201) thousand.
- Current liabilities amounted to 14,445 (9,664) thousand SEK.
- Total assets as of June 30, 2026 amounted to 180,026 (193,431) thousand SEK and consist mainly of acquired intangible assets of 69,994 (69,994) thousand SEK relating to the technology platform in Psyros Diagnostics Ltd. and intangible assets of 73,325 (57,297) thousand SEK relating to capitalized work for own account.
- The equity ratio was 84 percent (82).

Parent Company Development during Quarter 2, April 1 – June 30, 2026 and the period January 1 -June 30, 2026

(figures in parentheses refer to the corresponding period in the previous year)

REVENUE

- Other income for the quarter amounted to 780 (872) thousand SEK and for the period to 1,570 (1,659) thousand SEK. The income consisted mainly of invoiced costs to Psyros for management services, exchange rate gains and distribution income from NGM.

EXPENSES AND PROFITS

- The company's total operating expenses during the quarter amounted to 2,724 (2,950) thousand SEK and for the period to 5,438 (5,025) thousand SEK. The costs consisted mainly of external costs relating to consultancy costs for management services.
- The result for the quarter amounted to -1,944 (-2,401) thousand SEK and for the period to -3,868 (-3,689) thousand SEK.

FINANCING AND CASH FLOW

- Cash flow from operating activities amounted to -6,436 (-8,529) thousand SEK during the quarter and to -29,851 (-20,870) thousand SEK during the period.
- The total cash flow for the quarter amounted to -6,436 (-529) thousand SEK and for the period to -29,851 (-20,870) thousand SEK. The previous year's figures included a loan of 8,000 thousand SEK.
- Cash and cash equivalents at the end of the period amounted to 9,599 (1,960) thousand SEK.

EQUITY, RECEIVABLES AND LIABILITIES

(figures in brackets refer to 2025-12-31)

- Equity amounted to 89,188 (93,055) thousand SEK as of June 30, 2026.
- Total assets as of June 30, 2026 amounted to 92,864 (95,736) thousand SEK and consist primarily of shares in Psyros Diagnostics Ltd of 55,768 (55,768) thousand SEK.
- The equity/assets ratio was 96 percent (97).

Other information

RISKS AND UNCERTAINTIES
Prolight Diagnostics' operations are exposed to a number of risks and uncertainties, which to varying degrees may have a negative impact on continued operations. Both external, operational and financial risks may negatively affect the company in the short and long term. Prolight continuously works to inventory and manage the risks and uncertainties that the operations are exposed to in order to limit risk exposure and any impact if a risk arises. A detailed description of risks and risk management can be found in the annual report for 2025.

ACCOUNTING PRINCIPLES
This quarterly report has been prepared in accordance with Chapter 9 of the Annual Accounts Act. Prolight applies the Accounting Board's General Recommendations 2012:1 (K3) when preparing the company's financial reports.

AUDITOR'S REVIEW
The interim report has not been subject to an auditor's review.

RELATED PARTY TRANSACTIONS
No significant related party transactions have been carried out during the period except with the company's CEO and CFO. The transactions have been carried out on market terms.

OTHER
The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (equivalent to 83,405 shares) and 80,703 (equivalent to 80,703 shares) which may therefore result in dilution.

Prolight Diagnostics' share is traded under the ticker symbol PRLD on the NGM Growth Market.

GROUP FINANCIAL STATEMENTS

Income Statement, Summary Group

Amount in TSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full Year 2025
Operation income etc.					
Net Sales	0	0	0	0	0
Activated work for own account	6,959	449	16,043	3,222	15,349
Other income	2,840	13,945	4,042	15,607	26,854
Total income	**9,799**	**14,394**	**20,085**	**18,829**	**42,203**
Operating expenses					
Other external costs	-11,490	-8,074	-25,801	-17,551	-53,296
Personnel costs	-5,899	-5,329	-11,681	-10,804	-22,503
Depreciation/ Write-down intangible assets	-712	-16,336	-1,292	-16,753	-19,635
Other operating expenses	-2	-1	-3	-2	-18
Total expenses	**-18,104**	**-29,740**	**-38,779**	**-45,110**	**-95,452**
Operating result (EBIT)	**-8,304**	**-15,346**	**-18,694**	**-26,281**	**-53,249**
Result from financial investments					
Other interest income and similar items	0	0	0	0	492
Other interest expenses and similar items	0	-323	0	-323	-323
Total result from financial investments	**0**	**-323**	**0**	**-323**	**169**
Tax	0	2,928	0	2,928	3,372
Net loss	**-8,304**	**-12,740**	**-18,694**	**-23,676**	**-49,708**

Balance Sheet, Summary Group

Amount in TSEK	2026-06-30	2025-06-30	2025-12-31
ASSETS			
Subscribed but not paid-in capital	**0**	**100,298**	**90**
Fixed assets			
Intangible assets			
Capaitalized expenditure on development work and similar work	143,319	117,004	127,276
Intangible assets	12	2	15
	143,332	*117,006*	*127,291*
Tangible assets			
Equipment, tools, fixtures and fittings	10,302	5,583	8,243
	10,302	5,583	8,243
Total fixed assets	*153,633*	*122,589*	*135,534*
Current assets			
Other receivables	9,351	4,045	14,409
Prepaid expenses and accrued income	103	8,115	2,792
Cash and cash equivalents	16,939	5,652	40,606
Total current assets	*26,393*	*17,812*	*57,807*
Total assets	**180,026**	**240,699**	**193,431**
Equity			
Share capital	120,448	70,209	120,448
New share issue in progressl	0	50,149	0
Other paid in capital	279,880	280,733	279,881
Retained earnings	-230,472	-180,963	-181,274
Loss for the period	-18,694	-23,676	-49,708
Total equity	*151,162*	*196,452*	*169,347*
Provisions			
Accrued tax liabilities	14,419	14,863	14,419
Total Provisions	*14,419*	*14,863*	*14,419*
Current liabilities			
Other financial liabilities	0	8,000	0
Accounts payables	7,985	9,943	6,351
Other liabilities	1,345	1,675	849
Accrued expenses and deferred income	5,116	9,766	2,464
Total current liabilities	*14,445*	*29,384*	*9,664*
Total equity and liabilities	**180,026**	**240,699**	**193,431**

Changes in shareholders equity, Group

Amount in TSEK	Share capital	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2026-01-01	**120,448**	**279,880**	**-230,981**	**169,347**
Loss for the period			-18,694	-18,694
Foreign exchange rate adjustment			509	509
Shareholders equity 2026-06-30	**120,448**	**279,880**	**-249,166**	**151,162**

Amount in TSEK	Share capital	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2025-01-01	**70,209**	**237,870**	**-179,794**	**128,285**
Issue of new shares	50,239	50,148		100,387
Issuance cost		-8,139		-8,139
Loss for the period			-49,708	-49,708
Foreign exchange rate adjustment			-1,479	-1,479
Shareholders equity 2025-12-31	**120,448**	**279,880**	**-230,981**	**169,347**

Cash flow statement, Group

Amount in TSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full Year 2025
OPERATING ACTIVITIES					
Operating result (EBIT)	-8,305	-15,344	-18,694	-26,281	-53,249
Adjustment	712	85	1 292	503	7,079
Interests income	0	0	0	0	492
Cashflow from operating activities before changes in working capital	*-7,593*	*-15,259*	*-17,402*	*-25,778*	*-45,678*
Cash flow from changes in working capital					
Decrease (+) / increase (-) in operating receivables	10,294	-5,409	7,747	-2,225	-4,261
Decrease (-) / increase (+) in operating liabilities	5,065	15,969	4,781	14,128	12,934
Total Cash flow from changes in working capital	*15,359*	*10,560*	*12,528*	*11,903*	*8,673*
Cash flow from operating activities	**7,766**	**-4,699**	**-4,874**	**-13,875**	**-37,005**
INVESTMENT ACTIVITIES					
Investment in intangible assets	-6,959	-450	-16,043	-3,222	-15,349
Investment in tangible assets	-1,369	-145	-3,090	-284	-4,381
Cash flow from investment activities	**-8,328**	**-595**	**-19,133**	**-3,506**	**-19,730**
FINANCING ACTIVITIES					
Issue of new shares	0	0	0	0	81,437
Borrowing	0	8,000	0	8,000	0
Cash flow from financing activities	**0**	**8,000**	**0**	**8,000**	**81,437**
Cash flow for the period	**-561**	**2,706**	**-24,007**	**-9,381**	**24,702**
Cash and equivalents at the beginnging of period	17,262	3,173	40,606	15,734	15,734
Exchange rate differences in cash	239	-227	340	-701	170
Cash and equivalents at the end of period	**16,939**	**5,652**	**16,939**	**5,652**	**40,606**

Key ratio Group

	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full Year 2025
Net Sales, MSEK	-	-	-	-	-
Cash and equivalents, MSEK	16.9	3.1	16.9	3.1	40.6
Equity ratio, %	84	82	84	82	88
Quick asset ratio, %	395	61	183	61	598
Number of shares in the beginning of period	12,044,782	7,020,895	12,044,782	7,020,895	7,020,895
Average number of shares in the period	12,044,782	7,020,895	12,044,782	7,020,895	11,877,896
Number of shares in the end of period	12,044,782	7,020,895	12,044,782	7,020,895	12,044,782
Profit/Loss, MSEK	-8.3	-12.7	-18.7	-23.7	-49.7
Earnings per share, SEK	-0.69	-1.81	-1.55	-3.38	-4.13
Earnings per share after dilutions, SEK	-0.69	-1.81	-1.55	-3.38	-4.13

THE PARENT COMPANY'S FINANCIAL STATEMENTS

Income Statement, Summary Parent company

Amount in TSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full Year 2025
Operation income etc.					
Net Sales	0	0	0	0	0
Other income	780	872	1,570	1,659	3,283
Total operation incom etc.	*780*	*872*	*1,570*	*1,659*	*3,283*
Operating expenses					
Other external costs	-2,404	-2,631	-4,748	-4,338	-7,785
Personnel costs	-318	-318	-686	-686	-1,423
Amortization intangible assets	0		0	0	-1,836
Other operating expenses	-2	-1	-3	-2	-18
Total expenses	*-2,724*	*-2,950*	*-5,438*	*-5,025*	*-11,063*
Operating result	**-1,944**	**-2,078**	**-3,868**	**-3,366**	**-7,780**
Result from financial investments					
Write-down of investment in subsidiary	0	0	0	0	-61,385
Other interest income and similar items	0	0	0	0	492
Other interest expenses and similar items	0	-323	0	-323	-323
Total result from financial investments	*0*	*-323*	*0*	*-323*	*-61,216*
Net loss	**-1,944**	**-2,401**	**-3,868**	**-3,689**	**-68,996**

Balance Sheet, Summary, Parent company

Amount in TSEK	2026-06-30	2025-06-30	2025-12-31
ASSETS			
Subscribed but not paid-in capital	**0**	**100,298**	**90**
Fixed assets			
Capitalized expenditure on development work and similar work	0	1,836	0
Participation in group companies	55,768	55,768	55,768
Total fixed assets	*55,768*	*57,604*	*55,768*
Current assets			
Other receivables	387	408	300
Receivables from group company	27,008	17,029	0
Prepaid expenses and accrued income	103	8,116	128
Cash and cash equivalents	9,599	1,960	39,450
Total current assets	*37,096*	*27,513*	*39,878*
Total assets	**92,864**	**185,415**	**95,736**
Equity			
Restricted equity	133,495	183,554	133,495
Profit or loss brought forward / Loss for the year	-44,307	-24,430	-40,440
Total equity	*89,188*	*159,124*	*93,055*
Current liabilities			
Other financial liabilities	0	8,000	0
Accounts payables	1,086	7,810	406
Other liabilities	405	715	0
Accrued expenses and deferred income	2,186	9,766	2,275
Total current liabilities	*3,676*	*26,291*	*2,681*
Total equity and liabilities	**92,864**	**185,415**	**95,736**

Changes in shareholders equity, Parent company

	Restricted equity		Non resticted equity		
Amount in TSEK	Share capital	Statutory reserve	Share premium reserve	Profit/loss brought forward	Total Share-holders equity
Shareholders equity 2026-01-01	**120 448**	**13 047**	**266 834**	**-307 274**	**93 055**
Loss for the period				-3 868	**-3 868**
Shareholders equity 2026-06-30	**120 448**	**13 047**	**266 834**	**-311 142**	**89 188**

	Restricted equity		Non resticted equity		
Amount in TSEK	Share capital	Statutory reserve	Share premium reserve	Profit/loss brought forward	Total Share-holders equity
Shareholders equity 2025-01-01	**70 209**	**13 047**	**224 823**	**-238 278**	**69 801**
Issue of new shares	50 239		50 149		**100 388**
Issuance cost			-8 138		**-8 138**
Loss for the period				-68 996	**-68 996**
Shareholders equity 2025-12-31	**120 448**	**13 047**	**266 834**	**-307 274**	**93 055**

Cash flow statement summary, Parent company

Amount in TSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full Year 2025
THE ONGOING OPERATIONS					
Operating result	-1,944	-2,077	-3,868	-3,366	-7,780
Adjustment	0	12,999	0	12,998	-1,224
Interest income	0	0	0	0	493
Interest expenses	0	-323	0	-323	0
Cash flow from operating activities before changes in working capital	*-1,944*	*10,599*	*-3,868*	*9,309*	*-8,511*
Cash flow from changes in working capital					
Decrease (+) / increase (-) in operating receivables	-4,632	-14,144	-26,979	-25,193	-70
Decrease (-) / increase (+) in operating liabilities	140	-4,983	995	-4,986	215
Total changes in working capital	*-4,492*	*-19,128*	*-25,984*	*-30,179*	*145*
Cash flow from operating activities	**-6,436**	**-8,529**	**-29,851**	**-20,870**	**-8,366**
FINANCING ACTIVITIES					
Share issue	0	0	0	0	81,437
New loan	0	8,000	0	8,000	0
Cash flow from financing activities	**0**	**8,000**	**0**	**8,000**	**81,437**
Cash flow for the period	**-6,436**	**-529**	**-29,851**	**-12,870**	**24,620**
Cash and equivalents at the beginnging of period	16,035	2,489	39,450	14,830	14,830
Cash and equivalents at the end of period	**9,599**	**1,960**	**9,599**	**1,960**	**39,450**

Produkten är under utveckling. Design och specifikation kan ändras för den första produkten.

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/